Literature DB >> 36115921

Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.

Riki Okita1, Yuka Mimura-Kimura2, Nobutaka Kawamoto3, Naoki Yamamoto4,5, Masashi Umeda3, Masanori Okada3, Hidetoshi Inokawa3, Yusuke Mimura2, Tomoyuki Murakami2,6, Masao Nakata7, Kazunori Okabe3,8.   

Abstract

Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor immunity; however, the clinical impact of these parameters in resected malignant pleural mesothelioma (MPM) cases is unknown. We immunohistochemically evaluated the tumor infiltrated lymphocytes (TILs), PD1/PD-L1 axis, and expression of HLA class I in resected specimens from 58 patients with MPM who underwent extra-pleural pneumonectomy (EPP). Higher infiltration of CD3-TIL, CD8-TIL, and PD1-TIL, loss of HLA class I, and overexpression of PD-L1 by tumor cells (PD-L1 TC) or immune cells (PD-L1 IC) were observed in 34 (58.6%), 27 (46.6%), 41 (70.7%), 45 (77.6%), 29 (50.0%), and 33 (56.4%) of 58 cases, respectively. Interestingly, the CD3-TIL score positively correlated with PD-L1 TC and PD1-TIL scores. HLA class I expression level was inversely correlated with the expression levels of PD-L1 TC and PD-L1 IC. Multivariate analysis showed that age, histology, and node metastasis were independent prognostic factors for 5-year overall survival (OS) and loss of HLA class I coincided with a positive prognosis (p = 0.011). The concomitant lack of infiltrating CD8+ T cells with no loss of HLA class I predicted worse 5-year OS (p = 0.007). Moreover, cluster classifications among multiple immunoparameters showed that categories among CD3/PD-L1 TC/HLA class I (p = 0.043), CD8/PD1/HLA class I (p = 0.032), CD8/PD-L1 TC/HLA class I (p = 0.011), and PD1/PD-L1 TC/HLA class I (p = 0.032) predicted 5-year OS in EPP cases for MPM. These immunoparameters could guide surgical indications for patients with MPM.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Human leukocyte antigen class I (HLA class I); Malignant pleural mesothelioma (MPM); Prognostic factor; Programmed cell death protein-1/programmed cell death protein-1 ligand 1 axis (PD1/PD-L1 axis); Tumor microenvironment (TME)

Year:  2022        PMID: 36115921     DOI: 10.1007/s00262-022-03292-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  47 in total

1.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Paul Baas; Arnaud Scherpereel; Anna K Nowak; Nobukazu Fujimoto; Solange Peters; Anne S Tsao; Aaron S Mansfield; Sanjay Popat; Thierry Jahan; Scott Antonia; Youssef Oulkhouir; Yolanda Bautista; Robin Cornelissen; Laurent Greillier; Francesco Grossi; Dariusz Kowalski; Jerónimo Rodríguez-Cid; Praveen Aanur; Abderrahim Oukessou; Christine Baudelet; Gérard Zalcman
Journal:  Lancet       Date:  2021-01-21       Impact factor: 79.321

2.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

3.  Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Authors:  Morihito Okada; Takashi Kijima; Keisuke Aoe; Terufumi Kato; Nobukazu Fujimoto; Kazuhiko Nakagawa; Yuichiro Takeda; Toyoaki Hida; Kuninobu Kanai; Fumio Imamura; Satoshi Oizumi; Toshiaki Takahashi; Mitsuhiro Takenoyama; Hiroshi Tanaka; Jun Hirano; Yoshinobu Namba; Yuichiro Ohe
Journal:  Clin Cancer Res       Date:  2019-06-04       Impact factor: 12.531

4.  Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.

Authors:  B Seliger; C Harders; U Wollscheid; M S Staege; A B Reske-Kunz; C Huber
Journal:  Exp Hematol       Date:  1996-09       Impact factor: 3.084

5.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 6.  Natural history of HLA expression during tumour development.

Authors:  F Garrido; T Cabrera; A Concha; S Glew; F Ruiz-Cabello; P L Stern
Journal:  Immunol Today       Date:  1993-10

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

9.  A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern.

Authors:  Kathleen Kerrigan; Yeonjung Jo; Jonathan Chipman; Benjamin Haaland; Sonam Puri; Wallace Akerley; Shiven Patel
Journal:  JTO Clin Res Rep       Date:  2022-01-12

10.  Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma.

Authors:  Tomer Meirson; Francesca Pentimalli; Francesco Cerza; Giovanni Baglio; Steven G Gray; Pierpaolo Correale; Marija Krstic-Demonacos; Gal Markel; Antonio Giordano; David Bomze; Luciano Mutti
Journal:  JAMA Netw Open       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.